Description:
DelveInsight’s ‘Atopic Dermatitis - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan

Study Period: 2016-2027

Atopic Dermatitis Epidemiology
The Atopic Dermatitis (AD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Atopic Dermatitis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Atopic Dermatitis Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology, scenario of Atopic Dermatitis (AD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The disease epidemiology covered in the report is segmented by prevalent population of Atopic Dermatitis, Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the prevalent population of Atopic Dermatitis was estimated to be 40.78 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest AD Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Adults are largely affected with the atopic dermatitis Among EU5, France has been reported to have the highest prevalent population of atopic dermatitis.

Report Scope
- The report covers detailed overview of Atopic Dermatitis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The report provides the insight about the historical and forecasted patient pool of Atopic Dermatitis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
- The Report assesses the disease risk and burden and highlights the unmet needs of the disease
- The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in 7MM

Key strengths
• 10 Year Forecast of Atopic Dermatitis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Atopic Dermatitis
• Prevalent Cases according to segmentation: by Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults]

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Please Note - This report will available in 1 working day (24 hrs) after purchase.

Table Of Contents:
1. Report Introduction
2. Atopic Dermatitis Epidemiology Overview at a Glance
   2.1. Prevalent Population of Atopic Dermatitis in 2017
   2.2. Prevalent Population of Atopic Dermatitis in 2027
3. Disease Background and Overview
   3.1. Etiology
   3.2. Risk Factors
   3.3. Pathophysiology
   3.4. Atopic Dermatitis
      3.4.1. Pruritus Associated with Atopic Dermatitis
      3.4.2. Diagnosis
4. Epidemiology and Patient Population
   4.1. Disease Definition
   4.2. Population and Forecast Parameters
   4.3. Population Methods
      4.3.1. Total prevalent cases in US
      4.3.2. EU5
      4.3.3. Japan
   4.4. Prevalent Population of Atopic Dermatitis in 7MM
   4.5. Prevalent Population of Atopic Dermatitis in United States
   4.6. Prevalent Population of Atopic Dermatitis in Germany
   4.7. Prevalent Population of Atopic Dermatitis in France
4.8. Prevalent Population of Atopic Dermatitis in Italy
4.9. Prevalent Population of Atopic Dermatitis in Spain
4.10. Prevalent Population of Atopic Dermatitis in United Kingdom
4.11. Prevalent Population of Atopic Dermatitis in Japan
4.13. Prevalent Population of Atopic Dermatitis by Severity in Children in 7MM
4.14. Prevalent Population of Atopic Dermatitis by Severity in Adults in 7MM
4.15. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM
4.16. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases
4.17. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM
4.18. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM

5. Treatment Practices
6. Treatment Algorithm
6.1. Treatment Goals
6.2. Treatment Guidelines by American Academy of Dermatology
6.3. Japanese Guidelines for Atopic Dermatitis 2017

7. Current Unmet Need
8. Appendix
9. Report Methodology
9.1. Source Used
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight

List of Tables
Table 1: Targets focused by companies
Table 2: Concept of Atopic Dermatitis by Wise and Sulzberger
Table 3: Hanifin and Rajka Diagnostic Criteria
Table 4: United Kingdom Working Party diagnostic criteria
Table 5: American Academy of Dermatology Diagnostic Criteria
Table 6: Japanese Dermatological Association Diagnostic Criteria
Table 7: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
Table 8: Prevalent Population of Atopic Dermatitis in United States (2016-2027)
Table 9: Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
Table 10: Prevalent Population of Atopic Dermatitis in France (2016-2027)
Table 11: Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
Table 12: Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
Table 13: Prevalent Population of Atopic Dermatitis in United Kingdom (2016-2027)
Table 14: Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
Table 15: Prevalent Cases of Atopic Dermatitis by Severity in 7MM
Table 16: Prevalent Cases of Atopic Dermatitis by Severity in Children in 7MM
Table 17: Prevalent Cases of Atopic Dermatitis by Severity in Adult in 7MM
Table 18: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
Table 19: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
Table 20: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
Table 21: Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
Table 22: Topical corticosteroids used for the treatment of Atopic Dermatitis
Table 23: Topical Calcineurin Inhibitors (TCIs)
Table 24: Topical Phosphodiesterase Type-4 (PDE4) inhibitors
Table 25: Oral Corticosteroids
Table 26: Biologic medications
Table 27: Non-approved systemic immunomodulating agents
Table 28: Reasons for noncompliance with medication

List of Figures
Figure 1: Risk Factors for Atopic Dermatitis
Figure 2: Summary of pathogenic mechanisms in acute and chronic atopic dermatitis (AD)
Figure 3: Pathophysiology of Pruritus in Atopic Dermatitis
Figure 4: Mediators involved in Pathophysiology of Pruritus in Atopic Dermatitis
Figure 5: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
Figure 6: Total Prevalent Population of Atopic Dermatitis in United States (2016-2027)
Figure 7: Total Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
Figure 8: Total Prevalent Population of Atopic Dermatitis in France (2016-2027)
Figure 9: Total Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
Figure 10: Total Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
Figure 11: Total Prevalent Population of Atopic Dermatitis in the United Kingdom (2016-2027)
Figure 12: Total Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
Figure 13: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2016-2027)
Figure 14: Total Prevalent Population of Atopic Dermatitis by Severity in Children in 7 MM (2016-2027)
Figure 15: Total Prevalent Population of Atopic Dermatitis by Severity in Adult in 7 MM (2016-2027)
Figure 16: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
Figure 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
Figure 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
Figure 19: Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
Figure 20: General Treatment for Atopic Dermatitis
Figure 21: First Line and second line treatment of Atopic Dermatitis
Figure 22: Current stepped treatment options for Atopic dermatitis
Figure 23: Current Unmet Need for Atopic Dermatitis

**License Types:**

**Single User License (PDF)**

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in
presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Drug Pipeline

No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

About Us
Reports by Region
FAQ
Privacy Policy
TERMS & CONDITIONS
CONTACT

RECENT POSTS

What is drug pipeline research?
March 20

How to use market research to bring your idea to life?
March 11

How to gain business insights using syndicated market research?
March 10